) The Gene Expression Core represents a new Core facility for the UCCC and is most likely one of the first such cores to be peer-reviewed in the CCSG system. This facility is dedicated to making molecular gene expression technology available in a user-friendly manner. We utilize oligonucleotide arrays, cDNA arrays and quantitative RNA methodologies to investigate the changes in gene expression for our users. Affymetrix technology is used for the oligonucleotide arrays. These arrays are capable of analyzing human, mouse, rat and yeast species. Expressed sequence tag (EST) arrays of the mammalian species are available for gene discovery purposes. Custom cDNA arrays are constructed from sequence-verified clones. Quantitation of selected genes is made possible using real time PCR. With these capabilities, the objectives of the Gene Expression Core facility are to: 1) Analyze gene expression using both oligonucleotide and cDNA arrays; 2) Facilitate gene discovery with the inclusion of expressed sequence tag (EST) capability to the arrays; 3) Accurately quantitate gene expression using real time PCR; 4) Provide support for data analysis and bioinformatics by our data mining tool and our cluster analysis capabilities; 5) This facility has a commitment to utilizing a variety of approaches for expression analysis. This core was established in response to the technological advances in gene array, as well as the demand for high throughput expression analysis to investigate pathogenesis, therapeutics, genetic susceptibility and gene discovery in cancer research. The informatics aspect is of paramount importance, and three distinct analysis programs as well as a network are used to store and analyze the data. The facility has the capability and flexibility to adapt as the field of array technology changes. These changes are translated into upgrading the facility and its services. More complex analysis of gene expression arrays is available to members through the Biostatistics/Bioinformatics Core.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA046934-15
Application #
6589986
Study Section
Subcommittee G - Education (NCI)
Project Start
2002-05-06
Project End
2003-01-31
Budget Start
Budget End
Support Year
15
Fiscal Year
2002
Total Cost
$250,404
Indirect Cost
Name
University of Colorado Denver
Department
Type
DUNS #
065391526
City
Aurora
State
CO
Country
United States
Zip Code
80045
Petersen, Dennis R; Orlicky, David J; Roede, James R et al. (2018) Aberrant expression of redox regulatory proteins in patients with concomitant primary Sclerosing cholangitis/inflammatory bowel disease. Exp Mol Pathol 105:32-36
Couts, Kasey L; Bemis, Judson; Turner, Jacqueline A et al. (2018) ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK Isoforms. Mol Cancer Ther 17:222-231
Nicholson, Andrew G; Torkko, Kathleen; Viola, Patrizia et al. (2018) Interobserver Variation among Pathologists and Refinement of Criteria in Distinguishing Separate Primary Tumors from Intrapulmonary Metastases in Lung. J Thorac Oncol 13:205-217
Coleman, Carrie B; Lang, Julie; Sweet, Lydia A et al. (2018) Epstein-Barr Virus Type 2 Infects T Cells and Induces B Cell Lymphomagenesis in Humanized Mice. J Virol 92:
Thompson, Scott B; Wigton, Eric J; Krovi, Sai Harsha et al. (2018) The Formin mDia1 Regulates Acute Lymphoblastic Leukemia Engraftment, Migration, and Progression in vivo. Front Oncol 8:389
McCoach, Caroline E; Blakely, Collin M; Banks, Kimberly C et al. (2018) Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer. Clin Cancer Res 24:2758-2770
Sang, Allison; Danhorn, Thomas; Peterson, Jacob N et al. (2018) Innate and adaptive signals enhance differentiation and expansion of dual-antibody autoreactive B cells in lupus. Nat Commun 9:3973
Greaves, Sarah A; Peterson, Jacob N; Torres, Raul M et al. (2018) Activation of the MEK-ERK Pathway Is Necessary but Not Sufficient for Breaking Central B Cell Tolerance. Front Immunol 9:707
Flannery, Patrick C; DeSisto, John A; Amani, Vladimir et al. (2018) Preclinical analysis of MTOR complex 1/2 inhibition in diffuse intrinsic pontine glioma. Oncol Rep 39:455-464
Elder, Alan M; Tamburini, Beth A J; Crump, Lyndsey S et al. (2018) Semaphorin 7A Promotes Macrophage-Mediated Lymphatic Remodeling during Postpartum Mammary Gland Involution and in Breast Cancer. Cancer Res 78:6473-6485

Showing the most recent 10 out of 1634 publications